PSYENCE BIOMEDICAL LTD.

Psyence Biomedical is a life science biotechnology company that develops natural psilocybin products. Through its operating subsidiary, Biomed II, the company focuses on healing psychological trauma and its mental health consequences, particularly in the context of palliative care. Psyence has initiated clinical trials to evaluate the safety and efficacy of its product candidates. The company's priority is developing pharmaceutical-grade psilocybin to address psychological trauma and related disorders such as AjD, alcohol use disorder (AUD), other substance use disorders (SUDs), anxiety, depression, post-traumatic stress disorder (PTSD), and grief and bereavement, especially within palliative care. Its work also includes therapeutic protocols for medical and scientific research, including observational studies. Psyence's lead product candidate is PEX010, a capsule containing 25mg of naturally sourced psilocybin. PEX010 is currently being used in the company's Phase IIb Study. Psyence has a Research IP Agreement with Filament, a Canadian company and the proprietary owner of PEX010, for the licensing of PEX010. This license covers Psyence's designated fields of use: anxiety and depression, including associated ailments like PTSD, stress, grief, and adjustment disorder within the context of palliative care. Psyence has contracted Southern Star Research, an Australian full-service Contract Research Organization (CRO), to conduct a Phase IIb double-blind, randomized, low-dose controlled clinical trial. This trial assesses the efficacy and safety of PEX010 in psilocybin-assisted psychotherapy for treating AjD due to incurable cancer. Outsourcing this study helps the company operate more capital-efficiently. Psyence Biomedical conducts operations through subsidiaries in Ontario, Canada (Psyence Biomed II Corp, 100% owned), and Australia (Psyence Australia Pty Ltd.), and also owns a subsidiary in the Cayman Islands.